Table 1. Baseline characteristics of patients (n=203).
| Subgroup | Values |
|---|---|
| Age (years) | 68.03 (60.00–83.71) |
| Sex | |
| Male | 152 (74.88) |
| Female | 51 (25.12) |
| BMI (kg/m2) | 23.34 (16.53–31.48) |
| ≥22 | 85 (65.89) |
| <22 | 44 (34.11) |
| Unknown | 74 |
| ECOG score | |
| 0/1 | 190 (93.60) |
| 2/3 | 13 (6.40) |
| RAS gene mutation status | |
| Wild type | 59 (51.30) |
| KRAS | 54 (46.96) |
| NRAS | 2 (1.74) |
| Unknown | 88 |
| BRAF gene mutation status | |
| Wild type | 81 (96.43) |
| Mutant | 3 (3.57) |
| Unknown | 119 |
| Primary site | |
| Left | 134 (82.21) |
| Right | 29 (17.79) |
| Unknown | 40 |
| Liver metastasis | |
| Positive | 103 (50.74) |
| Negative | 100 (49.26) |
| Lung metastasis | |
| Positive | 118 (58.13) |
| Negative | 85 (41.87) |
| MMR gene status | |
| dMMR | 5 (5.10) |
| pMMR | 93 (94.90) |
| Unknown | 105 |
| Prior anti-VEGF therapy | |
| Used | 146 (73.00) |
| Not used | 54 (27.00) |
| Unknown | 3 |
| Lines of therapy | |
| Third-line | 123 (60.59) |
| Fourth-line | 52 (25.62) |
| Fifth-line | 19 (9.36) |
| ≥ Sixth-line | 9 (4.43) |
| Initial daily dose (mg) | |
| 40 | 5 (2.94) |
| 80 | 76 (44.71) |
| 120 | 43 (25.29) |
| 160 | 46 (27.06) |
| Unknown | 33 |
| Final daily dose (mg) | |
| 40 | 0 (0.00) |
| 80 | 51 (43.97) |
| 120 | 37 (31.90) |
| 160 | 28 (24.14) |
| Unknown | 87 |
Data are presented as mean (range) or n (%). BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; RAS, Rat sarcoma; KRAS, Kirsten rats arcomaviral oncogene homolog; NRAS, neuroblastoma RAS viral oncogene homolog; BRAF, V-Raf Murine Sarcoma Viral Oncogene Homolog B; MMR, mismatch repair; dMMR, deficiency of MMR; pMMR, proficiency of MMR; VEGF, vascular endothelial growth factor.